1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Alberto Abaterusso
Alberto Abaterusso
Articles (2139) 

Analysts Take Action on Health Care Stocks

JPMorgan initiates coverage of BeiGene, Brookline Capital Markets starts covering Celsion and Cellectar Biosciences

November 21, 2018 | About:

Analysts took action on health care stocks on Tuesday.

JPMorgan commenced coverage of BeiGene Ltd. (NASDAQ:BGNE) with an overweight rating. The analyst established a price target of $174 per share, which represents 38.3% upside from the share price of $125.8 at market close on Tuesday.

The share price has increased 46% over the 52 weeks of trading through Nov. 20. It is trading below the 50-, 100- and 200-day simple moving average lines.

The 52-week range is $77.54 to $220.1 per share. The stock has a market capitalization of $7.15 billion, a price-book ratio of 3.77 versus an industry median of 4.1 and a price-sales ratio of 42.41.

BeiGene develops molecularly-targeted and immuno-oncology drugs for the treatment of several forms of cancer.

The stock's recommendation rating is now 1.6 out of 5. Analysts predict a loss of $9.91 per share for fiscal 2018 and a loss of $10.36 per share for fiscal 2019.

The company does not pay a dividend.

GuruFocus assigned BeiGene a financial strength rating of 7 out of 10 and a profitability and growth rating of 3 out of 10.

Brookline Capital Markets started covering development-stage oncology pharmaceutical company Celsion Corp. (NASDAQ:CLSN), assigning a buy rating. The analyst set a price target of $9 per share, reflecting 400% upside from the closing price of $1.8 on Tuesday.

The stock has fallen 41% over the last 52 weeks. The current share price is below the 200-, 100- and 50-day simple moving average lines.

The stock has a market capitalization of $34.5 million. The 52-week range is $1.81 to $3.48 per share. The price-book ratio is 2.19 versus an industry median of 4.1 and the price-sales ratio is 65.72.

Celsion is developing and commercializing directed chemotherapy, RNA-based therapy and DNA-mediated immunotherapy products, which are used to treat several forms of cancer.

The stock has an average target price of $9 per share and a recommendation rating of 1 out of 5.

The company is not paying dividends.

Analysts predict a loss of $1.46 per share for fiscal 2018.

GuruFocus assigned Celsion a financial strength rating of 3 out of 10 and a profitability and growth rating of 3 out of 10.

Brookline Capital Markets has started covering shares of the clinical-stage biopharmaceutical company Cellectar Biosciences Inc. (NASDAQ:CLRB) with a buy rating. The analyst established a price target of $10 per share, which represents a 376.2% upside from the share price of $2.1 at market close on Tuesday.

The stock has fallen 85% for the 52 weeks through Nov. 20. It is trading below the 100- and 200-day simple moving average lines and is almost on par with the 50-day line.

The 52-week range is $2.03 to $15.9 per share. The stock has a market capitalization of $10.23 million and a price-book ratio of 0.61 versus an industry median of 4.1.

Cellectar Biosciences develops drugs to treat a broad range of cancers.

The recommendation rating is 1 out of 5 and the average target price is $8.2 per share.

The company does not have a dividend.

Analysts predict no earnings for fiscal 2018 and a loss of $3.78 per share for fiscal 2019.

GuruFocus assigns Cellectar Biosciences a financial strength rating of 4 out of 10 and a profitability and growth rating of 3 out of 10.

Disclosure: I have no positions in any securities mentioned in this article.

Read more here:

About the author:

Alberto Abaterusso
I am a contributor at GuruFocus. I primarily write about gold, silver and precious metals mining industries. My articles have also been widely linked by popular sites, including MarketWatch, Financial Times, 24hGold, Investopedia, Financial.org, CNBS, MSN Money, Zachs, Reuters and others. I hold a Master's Degree in Business Administration from Università degli Studi di Bari (Italy), Aldo Moro. I am based in The Netherlands.

You can follow me on Twitter at https://twitter.com/AAbaterusso

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by Alberto Abaterusso


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)